Ardelyx appoints Paul Korner as Executive Vice President and Chief Medical Officer

He beings extensive experience to the newly created role

Ardelyx, a California, US-based biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, has appointed Paul Korner to the newly created position of Executive Vice President and Chief Medical Officer.

Dr Korner brings extensive medical affairs and clinical development experience to the firm.

For 17 years, he has held various leadership positions with several global pharmaceutical companies. Over the past seven years, he has been President, Ferring International Pharmascience Centre US (FIPCUS) & Senior Vice President, US Development for Ferring Pharmaceuticals, where he built and led Ferring's US clinical development subsidiary responsible for gastroenterology, reproductive health, orthopaedics and urology therapeutic areas and was a member of senior global R&D management.

Dr Korner joined Ferring in 2008 as Vice President, Medical Affairs, responsible for pharmacovigilance, medical information and medical staff supporting Ferring's marketed products.

Prior to joining Ferring, Dr Korner was Vice President of Medical Affairs, Female Health at Bayer HealthCare Pharmaceuticals. He was also Senior Director of Clinical Research and Development, Women's Health and Musculoskeletal Bone Repair for Wyeth Research and as Director, Medical Affairs – GI and Women's Health for Solvay Pharmaceuticals.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now